Suppr超能文献

阿尔茨海默病患者脑脊液朊病毒蛋白浓度与认知功能。

CSF prion protein concentration and cognition in patients with Alzheimer disease.

机构信息

Clinical Dementia Center, Department of Neurology, Georg-August-University, Goettingen, Germany.

出版信息

Prion. 2013 May-Jun;7(3):229-34. doi: 10.4161/pri.23904. Epub 2013 Feb 13.

Abstract

BACKGROUND/OBJECTIVE: PrP (c) has been suggested to play a role in AD pathophysiology. CSF concentrations of PrP (c) have been shown to be reduced in AD compared with healthy controls. Furthermore, serum levels of PrP (c) have recently been reported to be associated with the cognitive status of healthy elderly subjects. Therefore, we hypothesized that CSF levels of PrP (c) could be associated with cognitive function of AD patients at the time of diagnosis.

METHODS

AD patients (n = 114) included into an observational study underwent CERAD testing and lumbar puncture at time of diagnosis / study inclusion. CSF PrP (c) was determined. Generalized linear models were fitted to assess the associations of PrP (c) plus a variety of possible confounding factors and CERAD subscale measures.

RESULTS

No association of CSF PrP (c) and cognitive status could be established, while other factors (i.e., use of antipsychotic drugs, use of anti-dementia drugs, female sex, pre-progression time) were related to worse cognitive function in some domains.

CONCLUSION

CSF PrP (c) appears not to be a useful biochemical surrogate of cognitive status in AD at the time of diagnosis. Follow-up analyses will examine possible associations with the speed of cognitive decline.

摘要

背景/目的:PrP(c)被认为在 AD 的病理生理学中发挥作用。与健康对照组相比,AD 患者的脑脊液(CSF)中 PrP(c)浓度降低。此外,最近有研究报告称,血清 PrP(c)水平与健康老年人的认知状态有关。因此,我们假设 CSF 中的 PrP(c)水平可能与 AD 患者在诊断时的认知功能有关。

方法

纳入到一项观察性研究中的 AD 患者(n = 114)在诊断/入组时接受了 CERAD 测试和腰椎穿刺。测定 CSF 中的 PrP(c)。使用广义线性模型来评估 PrP(c)与各种可能的混杂因素和 CERAD 子量表测量值之间的相关性。

结果

CSF PrP(c)与认知状态之间没有关联,而其他因素(如使用抗精神病药物、使用抗痴呆药物、女性、进展前时间)与某些认知域的认知功能下降有关。

结论

在诊断时,CSF PrP(c)似乎不是 AD 认知状态的有用生物化学替代标志物。随访分析将检查与认知衰退速度的可能关联。

相似文献

1
CSF prion protein concentration and cognition in patients with Alzheimer disease.
Prion. 2013 May-Jun;7(3):229-34. doi: 10.4161/pri.23904. Epub 2013 Feb 13.
2
Cerebrospinal fluid apolipoprotein E concentration and severity of cognitive impairment in patients with newly diagnosed Alzheimer's disease.
Am J Alzheimers Dis Other Demen. 2014 Feb;29(1):54-60. doi: 10.1177/1533317513505133. Epub 2013 Nov 24.
3
Plasma prion protein concentration and progression of Alzheimer disease.
Prion. 2014 Mar-Apr;8(2):210-4. doi: 10.4161/pri.27964. Epub 2014 Feb 18.
5
CSF biomarkers predict rate of cognitive decline in Alzheimer disease.
Neurology. 2009 Oct 27;73(17):1353-8. doi: 10.1212/WNL.0b013e3181bd8271.
6
Preclinical AD predicts decline in memory and executive functions in subjective complaints.
Neurology. 2013 Oct 15;81(16):1409-16. doi: 10.1212/WNL.0b013e3182a8418b. Epub 2013 Sep 18.
8
CSF VILIP-1 predicts rates of cognitive decline in early Alzheimer disease.
Neurology. 2012 Mar 6;78(10):709-19. doi: 10.1212/WNL.0b013e318248e568. Epub 2012 Feb 22.
9
Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia.
Exp Gerontol. 2017 Dec 15;100:45-53. doi: 10.1016/j.exger.2017.10.013. Epub 2017 Oct 17.

引用本文的文献

1
Cellular Prion Protein and Amyloid-β Oligomers in Alzheimer's Disease-Are There Connections?
Int J Mol Sci. 2025 Feb 27;26(5):2097. doi: 10.3390/ijms26052097.
2
Distinct populations of highly potent TAU seed conformers in rapidly progressing Alzheimer's disease.
Sci Transl Med. 2022 Jan 5;14(626):eabg0253. doi: 10.1126/scitranslmed.abg0253.
3
Cerebrospinal Fluid Mitochondrial DNA in Rapid and Slow Progressive Forms of Alzheimer's Disease.
Int J Mol Sci. 2020 Aug 31;21(17):6298. doi: 10.3390/ijms21176298.
4
Rapidly progressive Alzheimer's disease features distinct structures of amyloid-β.
Brain. 2015 Apr;138(Pt 4):1009-22. doi: 10.1093/brain/awv006. Epub 2015 Feb 15.
6
Biomarkers in Alzheimer's disease analysis by mass spectrometry-based proteomics.
Int J Mol Sci. 2014 May 6;15(5):7865-82. doi: 10.3390/ijms15057865.
7
Plasma prion protein concentration and progression of Alzheimer disease.
Prion. 2014 Mar-Apr;8(2):210-4. doi: 10.4161/pri.27964. Epub 2014 Feb 18.

本文引用的文献

1
Amyloid-β induced signaling by cellular prion protein and Fyn kinase in Alzheimer disease.
Prion. 2013 Jan-Feb;7(1):37-41. doi: 10.4161/pri.22212. Epub 2012 Sep 17.
2
Association of prion protein with cognitive functioning in humans.
Exp Gerontol. 2012 Dec;47(12):919-24. doi: 10.1016/j.exger.2012.08.001. Epub 2012 Aug 8.
3
Cellular prion protein is essential for oligomeric amyloid-β-induced neuronal cell death.
Hum Mol Genet. 2012 Mar 1;21(5):1138-44. doi: 10.1093/hmg/ddr542. Epub 2011 Nov 18.
5
Antipsychotics and cognitive function.
Psychogeriatrics. 2011 Jun;11(2):79-82. doi: 10.1111/j.1479-8301.2011.00372.x.
7
Unaltered prion protein expression in Alzheimer disease patients.
Prion. 2011 Apr-Jun;5(2):109-16. doi: 10.4161/pri.5.2.16355. Epub 2011 Apr 1.
9
Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD.
Am J Psychiatry. 2011 Aug;168(8):831-9. doi: 10.1176/appi.ajp.2011.08121844. Epub 2011 May 15.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验